Cancer news covering oncology trials, treatment advances, screening guidelines, epidemiology, and patient outcomes.
Johnson & Johnson released Phase 2b COPERNICUS study data showing that less-frequent dosing with RYBREVANT FASPRO and LAZCLUZE may enhance treatment experiences. The results target patients with previously untreated advanced non-small cell lung cancer, highlighting potential improvements in therapeutic protocols.
Moderna and Merck announced that their Phase 3 trial for intismeran autogene, an AI-built personalized cancer therapy, met its primary endpoint in melanoma patients. This marks the first positive Phase 3 outcome for individually constructed treatments, though manufacturing timelines of four to eight weeks remain a scaling constraint.
Researchers at Feinstein Institutes found a specialized diet restricting arginine and adding ornithine slowed high-grade glioma growth in mice by targeting GAMT Deficiency. The approach is distinct from standard ketogenic diets and could pave the way for human clinical trials.
Keith Stewart, director of the Princess Margaret Cancer Centre, argues that early-detection blood tests represent a transformative shift in cancer care by identifying tumors before symptoms appear. He contends this technology could prevent disease progression, though he notes that current tests lack regulatory approval and require further research to validate their long-term efficacy and safety.
UC San Francisco researchers identified a mechanism where stiff breast tissue attracts immune cells that release DNA-damaging chemicals, raising cancer risk. The study published in Cancer Cell found that physical stiffness prompts macrophages to activate the STAT3 signaling pathway, explaining why dense breast tissue is associated with higher tumor formation rates.
Oncologist Dr. Tiffany Pompa challenges the medical misconception that cancer lumps are always hard, fixed, and painless. She argues that soft, tender, or mobile lumps can also be malignant, warning that reliance on the 'classic' presentation leads to false reassurance and delayed diagnoses among patients and clinicians.
Medical researchers are warning that rising vaccine hesitancy, partly attributed to the Trump administration, could significantly reduce the effectiveness and adoption of new cancer treatments. This concern arises as Moderna and Merck announce positive late-stage trial results for personalized mRNA skin cancer vaccines and promising immune responses in breast cancer trials.
The FDA awarded Breakthrough Therapy Designation to Revolution Medicines' pancreatic cancer treatment Rasonque. The designation applies to the drug used in combination with gemcitabine and nab-paclitaxel for metastatic pancreatic adenocarcinoma, based on Phase 1-2 trial data showing encouraging anti-tumor activity.
AstraZeneca announced positive Phase III results for Enhertu in treating HER2-mutant lung cancer, significantly improving progression-free survival. However, its breast cancer therapy Etcamah failed to meet its primary endpoint, marking a mixed period for the company's oncology pipeline.
An eight-year update of the Phase III ADAURA trial presented at IASLC 2026 confirms sustained overall survival benefits for adjuvant osimertinib in resected EGFR-mutated non-small cell lung cancer. Patients with stage II-IIIA disease showed a 16-percentage-point survival advantage compared to placebo, reinforcing the drug's status as standard of care.